Zhengyuan Zhou

Zhengyuan Zhou

Auto-generated profile, based on publicly available information

Zhengyuan Zhou

Department of Radiology, Duke University Medical Center, Durham, North Carolina 27710, United States

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2017 in Molecular Imaging and Biology
Verified
Journal Article
Closed access
PDF file
ZZZhengyuan Zhou
Zhengyuan Zhou
GVGanesan Vaidyanathan
Ganesan Vaidyanathan
DMDarryl McDougald
Darryl McDougald
CKChoong Mo Kang
Choong Mo Kang
IBIrina Balyasnikova
Irina Balyasnikova
MZMichael R. Zalutsky
Michael R. Zalutsky

1 October 2016 in Biomaterials
Verified
Journal Article
Closed access
WFWei Fan
Wei Fan
WSWen Shi
Wen Shi
WZWenting Zhang
Wenting Zhang
YJYinnong Jia
Yinnong Jia
ZZZhengyuan Zhou
Zhengyuan Zhou
JGJered C. Garrison
Jered C. Garrison

1 December 2015 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
GVGanesan Vaidyanathan
Ganesan Vaidyanathan
DMDarryl McDougald
Darryl McDougald
JCJaeyeon Choi
Jaeyeon Choi
MPMarek Pruszyński
Marek Pruszyński
EKEftychia Koumarianou
Eftychia Koumarianou
MZMichael R. Zalutsky
Michael R. Zalutsky
A nanobody 5F7 was labeled with 18F using [18F]RL-I, a residualizing label, with the preservation of affinity and immunoreactivity to HER2.

1 November 2015 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
YJYinnong Jia
Yinnong Jia
WSWen Shi
Wen Shi
ZZZhengyuan Zhou
Zhengyuan Zhou
NWNilesh K. Wagh
Nilesh K. Wagh
WFWei Fan
Wei Fan
JGJered C. Garrison
Jered C. Garrison

29 July 2013 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
ZZZhengyuan Zhou
Zhengyuan Zhou
NWNilesh K. Wagh
Nilesh K. Wagh
SOSunny M. Ogbomo
Sunny M. Ogbomo
WSWen Shi
Wen Shi
YJYinnong Jia
Yinnong Jia
JGJered C. Garrison
Jered C. Garrison
Receptor-targeted agents, such as gastrin-releasing peptide receptor (BB2r)–targeted peptides, have been investigated extensively in preclinical and clinical studies. In an attempt to increase the effectiveness of diagnostic or radiotherapeutic agents, we have begun to explore the incorporation of the hypoxia-selective prodrug 2-nitroimidazole into receptor-targeted peptides. Hypoxia is a well-known characteristic of many solid tumors, including breast, prostate, and pancreatic cancers. The aim of this approach is to use the hypoxia-trapping capability of 2-nitroimidazoles to increase the retention of the agent in hypoxic, BB2r-positive tumors. We have demonstrated that incorporation of one or more 2-nitroimidazoles into the BB2r-targeted peptide significantly increases the in vitro retention of the agent in hypoxic prostate cancer cells. The study described herein represents our first investigation of the in vivo properties of these hypoxia-enhanced BB2r-targeted agents in a PC-3 xenograft mouse model. Methods: Four 111In-labeled BB2r-targeted conjugates—111In-1, 111In-2, 111In-3, and 111In-4, composed of 2-nitroimidazole moieties of 0, 1, 2, and 3, respectively—were synthesized, labeled, and purified. The BB2r binding affinities, externalization, and protein-association properties of these radioconjugates were assessed using the BB2r-positive PC-3 human prostate cancer cell line under hypoxic and normoxic environments. The in vivo biodistribution and micro-SPECT/CT imaging of the 111In-1, 111In-2, and 111In-4 radioconjugates were investigated in PC-3 tumor–bearing severely combined immunodeficient mice. Results: All conjugates and natIn-conjugates demonstrated nanomolar binding affinities. 111In-1, 111In-2, 111In-3, and 111In-4 demonstrated 41.4%, 60.7%, 69.1%, and 69.4% retention, correspondingly, of internalized radioactivity under hypoxic conditions relative to 34.8%, 35.3%, 33.2%, and 29.7% retention, respectively, under normoxic conditions. Protein-association studies showed significantly higher levels of association under hypoxic conditions for 2-nitroimidazole–containing BB2r-targeted radioconjugates than for controls. On the basis of the initial 1-h uptake in the PC-3 tumors, 111In-1, 111In-2, and 111In-4 demonstrated tumor retentions of 1.5%, 6.7%, and 21.0%, respectively, by 72 h after injection. Micro-SPECT/CT imaging studies of 111In-1, 111In-2, and 111In-4 radioconjugates resulted in clear delineation of the tumors. Conclusion: On the basis of the in vitro and in vivo studies, the BB2r-targeted agents that incorporated 2-nitroimidazole moieties demonstrated improved retention. These results indicate that further exploration into the potential of hypoxia-selective trapping agents for BB2r-targeted agents, as well as other targeted compounds, is warranted.

9 November 2017 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
WZWenting Zhang
Wenting Zhang
WFWei Fan
Wei Fan
ZZZhengyuan Zhou
Zhengyuan Zhou
JGJered Garrison
Jered Garrison